top of page

ALX Oncology's CEO on CD47 after Gilead's magrolimab news last week, and why he believes his asset is fundamentally different

Jason Lettmann describes how he believes having an inactive Fc domain makes all the difference in the CD47 space, and he previews the clinical data we will see over the course of 2024 to help further this hypothesis.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page